A Phase II Randomized Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor, Versus BAY 43-9006 Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer.

Trial Profile

A Phase II Randomized Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor, Versus BAY 43-9006 Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2015

At a glance

  • Drugs Sorafenib (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Apr 2014 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 12 Dec 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top